Home  |  Contact

UniProtKB/Swiss-Prot P02766: Variant p.Ala65Thr

Transthyretin
Gene: TTR
Variant information

Variant position:  65
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Alanine (A) to Threonine (T) at position 65 (A65T, p.Ala65Thr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and hydrophobic (A) to medium size and polar (T)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In AMYL-TTR; amyloid cardiomyopathy.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  65
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  147
The length of the canonical sequence.

Location on the sequence:   AINVAVHVFRKAADDTWEPF  A SGKTSESGELHGLTTEEEFV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         AINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFV

Chimpanzee                    AINVAVHVFKKAADETWEPFASGKTSESGELHGLTTEEEFV

Mouse                         AVDVAVKVFKKTSEGSWEPFASGKTAESGELHGLTTDEKFV

Rat                           AVDVAVKVFKKTADGSWEPFASGKTAESGELHGLTTDEKFT

Pig                           AVNVGVKVFKKAADGTWEPFALGKTSEFGELHGLTTDEKFV

Bovine                        AANVGVKVFKKAADETWEPFASGKTSESGELHGLTTEDKFV

Rabbit                        AVDVSVHVFKKAADETWEPFASGKTSKTGELHGLTTSEKFV

Sheep                         AANVGVKVFKKAADETWEPFASGKTSDSGELHGLTTEDKFV

Chicken                       AANVAVKVFKKAADGTWQDFATGKTTEFGEIHELTTEEQFV

Xenopus laevis                AANLLVNVFRQTESGKWEQITSGKTTELGEIHNLTTDEQFT

Xenopus tropicalis            AANLLVQVFRNT-EGNWELISSGKTTELGEIHNIITDEQFT

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 21 – 147 Transthyretin
Binding site 74 – 74 Thyroid hormones
Modified residue 62 – 62 4-carboxyglutamate; in a patient with Moyamoya disease
Modified residue 72 – 72 Phosphoserine
Beta strand 61 – 68


Literature citations

A new transthyretin mutation associated with amyloid cardiomyopathy.
Saraiva M.J.M.; Almeida M.R.; Sherman W.; Gawinowicz M.; Costa P.; Costa P.P.; Goodman D.S.;
Am. J. Hum. Genet. 50:1027-1030(1992)
Cited for: VARIANT AMYL-TTR THR-65;

Genetic microheterogeneity of human transthyretin detected by IEF.
Altland K.; Benson M.D.; Costello C.E.; Ferlini A.; Hazenberg B.P.C.; Hund E.; Kristen A.V.; Linke R.P.; Merlini G.; Salvi F.; Saraiva M.J.; Singer R.; Skinner M.; Winter P.;
Electrophoresis 28:2053-2064(2007)
Cited for: VARIANTS AMYL-TTR PRO-32; ILE-40; SER-44; ALA-50; MET-50; LEU-53; VAL-53; PRO-56; THR-65; ALA-67; ALA-69; ILE-69; ALA-80; LEU-84; LEU-88; ALA-91; TYR-97; PHE-98; SER-104; ASN-104; THR-104; ALA-114; GLY-117; ASN-126; MET-127; VAL-127; MET-131 AND ILE-142; VARIANTS ILE-33; SER-121 AND THR-129; VARIANT CHICAGO MET-139;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.